Stockscreener 앱 받기
1.21
3.20%
-0.04
시간 외 거래:
1.21
전일 마감가:
$1.25
열려 있는:
$1.24
하루 거래량:
210.51K
Relative Volume:
0.41
시가총액:
$74.96M
수익:
-
순이익/손실:
$-73.79M
주가수익비율:
-0.6576
EPS:
-1.84
순현금흐름:
$-77.44M
1주 성능:
-1.63%
1개월 성능:
+16.35%
6개월 성능:
-39.80%
1년 성능:
-67.47%
1일 변동 폭
$1.20
$1.246
1주일 범위
$1.195
$1.25
52주 변동 폭
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
명칭
Pyxis Oncology Inc
전화
(617) 221-9059
주소
321 HARRISON AVENUE, BOSTON
PYXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.21 | 76.20M | 0 | -73.79M | -77.44M | -1.84 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-08-08 | 개시 | Stifel | Buy |
| 2024-05-07 | 재개 | Jefferies | Buy |
| 2024-02-09 | 개시 | BTIG Research | Buy |
| 2024-01-23 | 개시 | Leerink Partners | Outperform |
| 2023-09-05 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-02 | 개시 | BofA Securities | Neutral |
| 2021-11-02 | 개시 | Credit Suisse | Outperform |
| 2021-11-02 | 개시 | Jefferies | Buy |
모두보기
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
Northern Trust Corp Sells 15,449 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments - TipRanks
Millennium Management LLC Has $4.65 Million Stock Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Consensus PT from Analysts - Defense World
Q2 EPS Estimates for Pyxis Oncology Cut by HC Wainwright - Defense World
HC Wainwright Weighs in on Pyxis Oncology Q1 Earnings - Defense World
Leerink Partnrs Comments on Pyxis Oncology FY2029 Earnings - Defense World
Pyxis Oncology (PYXS) Receives Reiterated Buy Rating from Analys - GuruFocus
Dimensional Fund Advisors LP Raises Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology : May 2025 Corporate Deck (9474da) - marketscreener.com
Pyxis Oncology Reports Q1 Loss and Business Update - TipRanks
Pyxis Oncology (PYXS) Advances Cancer Treatment Research | PYXS Stock News - GuruFocus
Pyxis Oncology, Inc. SEC 10-Q Report - TradingView
Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pyxis Oncology : May 2025 Corporate Deck (c8a9bd) - marketscreener.com
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 12,924 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology to Participate in Two Upcoming Investor Conferences - The Manila Times
Pyxis Oncology, Inc. CEO Lara S. Sullivan to Participate in Upcoming Investor Conferences - Nasdaq
Next-Gen Cancer Drug Developer Pyxis Oncology Sets Major Investor Conference Schedule for May-June - Stock Titan
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - Defense World
New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs - Baystreet.ca
Renaissance Technologies LLC Acquires 133,018 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Inc (PYXS) is a good investment, but the stock may be overvalued - uspostnews.com
Taking a look at what insiders are doing to gauge the Pyxis Oncology Inc (PYXS)’s direction - knoxdaily.com
Pyxis Oncology reveals promising preclinical data for cancer drug - Investing.com
Pyxis Oncology reveals promising preclinical data for cancer drug By Investing.com - Investing.com UK
Pyxis Oncology Highlights Promising Preclinical Data for Micvotabart Pelidotin (MICVO) in Cancer Therapy at AACR 2025 - Nasdaq
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - TradingView
Novel Cancer Drug Shows 91% Tumor Inhibition in Breakthrough Study | PYXS Stock News - Stock Titan
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Pyxis Oncology Inc (PYXS) requires closer examination - uspostnews.com
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance
Pyxis Oncology Inc (PYXS) receives a Mkt perform rating from William Blair - knoxdaily.com
Pyxis Oncology Inc (PYXS) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Sei Investments Co. Acquires New Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
American Century Companies Inc. Has $468,000 Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - marketscreener.com
Pyxis Oncology stock plunges to 52-week low of $0.86 - Investing.com Australia
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
CEO Spotlight: Pyxis Oncology to Reveal Latest Cancer Drug Strategy at Elite Stifel Forum - Stock Titan
Pyxis Oncology stock hits 52-week low at $0.98 amid downturn - Investing.com Canada
Is it possible to buy Pyxis Oncology Inc(PYXS) shares at a good price now? - US Post News
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - The Manila Times
Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate - MarketScreener
Pyxis Oncology Inc (PYXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):